Floatz logo

DARATUMUMAB

Solid Tumors

Hellenic Society of Hematologymonoclonal_antibodyPhase 1/2Active
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
65/ 100

Competitive context

207 Active assets in the Solid Tumors cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Hellenic Society of Hematology
Phase 3BB
FILGRASTIM
Ankara Etlik City Hospital
Phase 2BB
Carboplatin
Bristol-Myers Squibb
Phase 3BB
Ribociclib
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 4B
ETOPOSIDE
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2B

View all 50 →

Same molecule, other indications

DARATUMUMAB is also rated in:

plasma cell myelomaDormant
BB
Indicative ·
67 / 100
View asset →
smoldering plasma cell myelomaDormant
BB
Indicative ·
65 / 100
View asset →
diffuse large B-cell lymphomaDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →